Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer

Anti-Cancer Drugs

Volumn 14, Issue 1, 2003, Pages 79-85

  Moehler, Markus ^a   Hoffmann, Tanja ^a   Zanke, Christine ^b   Hohl, Horst ^b   Burg, Helmut ^c   Ehscheid, Peter ^d   Schwindt, Peter ^e   Adami, Bernd ^f   Schroeder, Martin ^g   Klein, Ortwin ^h   Baldus, Michael ⁱ   Galle, Peter R ^a   Heike, Michael ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Outpatient Clin Hosp Bad Ems   (Germany)

^c Outpatient Clin Hosp Simmern   (Germany)

^d Outpatient Clin Hosp Neuwied   (Germany)

^e Outpatient Clin Hosp Andernach   (Germany)

^f Outpatient Clin Gen Practice Alzey   (Germany)

^g Outpatient Clin Hosp St V   (Germany)

^h Outpatient Clin Gen Pract K   (Germany)

ⁱ Outpatient Clin Gen Pract R   (Germany)

Author keywords

5 Fluorouracil; Colorectal cancer; Irinotecan; Metastatic disease; Oxaliplatin neoadjuvant

Indexed keywords

BUDESONIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG EMBOLISM; MALE; METASTASIS; MORTALITY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTPATIENT CARE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0037271431     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200301000-00011     Document Type: Article

References (28)

1. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93:824-842.
2. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330:1136-1142.
3. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001; 13:275-286.
4. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
5. Pooh MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407-1418.
6. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14-20.
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
9. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
10. Giacchetti S, Perpoint B, Zigani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
11. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49:5077-5082.
12. Rothenberg ML. Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 2001; 6:66-80.
13. Cunningham D, Pyrrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
14. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
15. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fuorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801-3807.
16. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345:144-146.
17. Saltz LB, Kanowitz J, Kemeny NE, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996; 14:2959-2967.
18. Camptosar labeling does not need major changes, advisory cmte says. Health News Daily 2001; December 7:10.
19. Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86:446-449.
20. Lenfers BH, Loeffler TM, Droege CM, et al. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999; 10:1251-1253.
21. Gandia D, Abigerges D, Armand JP, et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993; 11:196-197.
22. Maisey NR, Norman A, Watson M, et al. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 2002; 38:1351-1357.
23. Aldrighetti L, Arru M, Angeli E, et al. Percutaneous vs. surgical placement of hepatic artery indwelling catheters for regional chemotherapy. Hepatogastroenterology 2002; 49:513-517.
24. Shankar A, Leonard P, Renaut AJ, et al. Neo-adjuvant therapy improves resectability rates for colorectal liver metastases. Ann R Coll Surg Engl 2001; 83:85-88.
25. Giacchetti S, Itzhahi M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-669.
26. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509-522.
27. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA + Oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002:512 (abstr).
28. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: Oxaliplatin (OXAL) or CPT-11 + 5-Fluorouracil (5FU)/Leucovorin (LV) or OXAL+CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI intergroup study. Proc Am Soc Clin Oncol 2002:511 (abstr).